Advances in the Pharmacology of Depression and Mood Disorders
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 2
Special Issue Editor
Interests: neuropharmacology; serotonergic system; antidepressant research; rapid antidepressant treatments, neuroplasticity; hippocampus; brain circuitries
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recently, the field of depression and mood disorders has been characterized by the emergence of several new avenues of research. This development mainly began with studies showing that ketamine, administered at a low, subanaesthetic dose, can relieve the symptoms of some depressed patients with an impressive rapidity of action when compared to the canonical classes of antidepressant molecules. This discovery paved the way for new hypotheses, and subsequently a number of innovative concepts have been developed, especially for the purpose of achieving fast-acting treatments. One of the most illustrative examples probably resides in the current trials conducted with other psychedelic drugs, such as LSD or psylocibin. Additional paths of research have arisen, including the role played by the different types of glutama-tergic receptors in the regulation of neurotransmission and synaptic plasticity within brain regions involved in mood control. Still, in parallel, researchers have also focused on the serotonergic (5-HT) system, more classically studied, and new targets have been identified among the different 5-HT receptors (e.g., the 5-HT4 and 5-HT6 types).
Due to this conceptual development, the theories that have been proposed up to this point to address the neuropharma-cology of depression and mood disorders, such as the “plastic hypothesis” or “the serotonergic/aminergic theory”, need to be revisited and/or challenged. For instance, the role played by 5-HT and other monoamines in the therapeutic poten-tial of psychedelics remains virtually unknown, and, similarly, the ability of 5-HT pharmacological agents to modulate the neuroplastic and circuit changes induced by these same compounds has not yet been studied. This Special Issue welcomes both research papers and reviews addressing these points by proposing new mechanisms of action and/or hypotheses. Studies presenting potential new targets are also encouraged.
Dr. Guillaume Lucas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- new antidepressants
- rapid antidepressant action
- ketamine in depression
- glutamatergic antidepressants
- psychedelics in depression
- 5-HT receptors as targets for antidepressant research
- neu-roplasticity and antidepressant action
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
